Skip to main content
Premium Trial:

Request an Annual Quote

New York Approves Natera's CLIA Laboratory

NEW YORK (GenomeWeb News) – Natera today announced that New York has issued a permit for the company's CLIA laboratory, allowing Natera to offer its preconception and prenatal tests to expecting parents in the state.

The New York State Department of Health issued a clinical laboratory permit for the company's CLIA-certified laboratory in San Carlos, Calif. Approval includes Natera's Panorama non-invasive prenatal test for fetal aneuploidies, the firm said.

The test, launched earlier this year, uses a blood draw to detect trisomy 21, 18, and 13, as well as monosomy X, triploidy, and sex chromosome aneuploidies. It employs Natera's algorithm called Next Generation Aneuploidy Testing Using SNPs to analyze cell-free DNA from both the mother and the fetus.

Natera last week announced an agreement with DiagCor to bring Panorama to Hong Kong. It has deals with Quest Diagnostics, Bio-Reference Laboratories, and Arup Laboratories to offer its test in the US.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.